MX 1122

Drug Profile

MX 1122

Alternative Names: MX-1122

Latest Information Update: 26 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxim Pharmaceuticals
  • Class
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Reperfusion injury

Most Recent Events

  • 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
  • 24 Jul 2002 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
  • 06 May 2002 Preclinical trials in Reperfusion injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top